Today: 23 January 2026
Subscribe
Browse Category

NASDAQ:NEBI News 13 January 2026 - 16 January 2026

Nebius stock rises as Morgan Stanley starts coverage and ClickHouse funding puts stakes back in focus

Nebius stock rises as Morgan Stanley starts coverage and ClickHouse funding puts stakes back in focus

New York, January 16, 2026, 12:57 PM EST — Regular session underway. Nebius Group N.V. shares climbed roughly 3.9% to $107.89 by midday Friday. The stock swung between $100.80 and $110.47 during the session, with about 9.8 million shares changing hands. This move keeps the Nasdaq-listed AI infrastructure player in focus as traders chase momentum in “compute” stocks. The race…
16 January 2026
·····
Nebius stock slips after Monday’s 10% pop as AI infrastructure trade turns choppy

Nebius stock slips after Monday’s 10% pop as AI infrastructure trade turns choppy

NEW YORK, Jan 13, 2026, 13:37 ET — Regular session Nebius Group N.V. shares slipped 1.4% on Tuesday, shedding some of Monday’s gains amid a broader pullback in high-growth AI infrastructure stocks. The stock traded last at $105.85, fluctuating between $104.35 and $108.36 throughout the session. The pullback is significant because Nebius now serves as a momentum gauge for demand…
13 January 2026
·····

Stock Market Today

  • Johnson & Johnson and Merck: Two Healthcare Stocks to Hold for 20 Years
    January 23, 2026, 1:21 PM EST. Johnson & Johnson (JNJ) and Merck (MRK) stand out as durable picks for long-term investors, driven by strong healthcare franchises. Merck's oncology focus, led by its blockbuster cancer drug Keytruda, positions it for continued sales growth despite looming patent expiration in 2028. The company also expands with new approvals and formulations to sustain momentum. Johnson & Johnson benefits from a diversified portfolio across pharmaceuticals and medical devices, consistently delivering revenue and earnings, even amid challenges. Both stocks offer attractive dividend yields - Merck at 3.1% with nearly doubling payouts historically, and Johnson & Johnson at 2.35%. Their scale, innovation, and dividend track records make them solid candidates for wealth accumulation over two decades, despite short-term volatility.
Go toTop